Health Economics›Non-small cell lung cancer squamous›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Non-small cell lung cancer squamous · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 17 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Ipilimumab Variant #01	—	R 788 598	21d	—	13.4 mo	—	—	1
Carboplatin and Paclitaxel (CP) and Pembrolizumab Variant #03	—	R 248 201	42d	6.8 mo	18.7 mo	5	R 1 241 005 PFS proxy	5
Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab Variant #01	—	R 110 106	21d	6.8 mo	18.7 mo	10	R 1 101 061 PFS proxy	5
Carboplatin and Paclitaxel (CP) and Ipilimumab, Nivolumab Variant #01 Partial	—	R 81 233	21d	—	15.8 mo	—	—	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~29.2 mo	~9	~R 707 538 PFS proxy · indirect	13
Carboplatin and nab-Paclitaxel (CnP) and Atezolizumab Variant #01	—	R 78 195	21d	6.3 mo	—	10	R 781 952 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 38 912	21d	5.7 mo	15.2 mo	9	R 350 208 PFS proxy	8
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	20.2 mo	—	30	R 937 639 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) and Tislelizumab Variant #01 Partial	—	R 27 914	21d	8.6 mo	—	13	R 362 879 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) and Serplulimab Variant #01 Partial	—	R 27 914	21d	8.3 mo	22.7 mo	13	R 362 879 PFS proxy	2
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	5.5 mo	9.9 mo	3	R 46 014 PFS proxy	4
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	4.9 mo	12.9 mo	8	R 40 246 PFS proxy	14
Cisplatin and Gemcitabine (GC) and Necitumumab Variant #01 Partial	—	R 3 928	21d	—	11.5 mo	—	—	1
Carboplatin and Gemcitabine (GCb) and Sintilimab Variant #01 Partial	—	R 3 868	21d	5.5 mo	—	8	R 30 945 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	5.3 mo	12.9 mo	8	R 29 304 PFS proxy	7
Cisplatin and Gemcitabine (GC) and Sintilimab Variant #01 Partial	—	R 3 218	21d	5.5 mo	—	8	R 25 741 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Sugemalimab Variant #01 Partial	—	R 2 239	21d	9.0 mo	25.3 mo	14	R 31 352 PFS proxy	4
Carboplatin and Paclitaxel (CP) and Tislelizumab Variant #01 Partial	—	R 2 239	21d	7.6 mo	22.8 mo	12	R 26 873 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Penpulimab Variant #01 Partial	—	R 2 239	21d	7.6 mo	—	12	R 26 873 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Camrelizumab Variant #01 Partial	—	R 2 239	21d	—	—	—	—	1
Docetaxel and Nedaplatin Variant #01 Partial	—	R 1 656	21d	—	13.6 mo	—	—	1
Carboplatin and S-1 Variant #01 Partial	—	R 1 026	21d	—	~15.2 mo	—	—	1
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	4.2 mo	11.4 mo	7	R 3 144 PFS proxy	2
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	10.9 mo	—	—	1

24 of 24 regimens shown